vascular smooth muscle cells human coronary artery vsmc (Cambrex)
90
Structured Review
Cambrex
vascular smooth muscle cells human coronary artery vsmc
Vascular Smooth Muscle Cells Human Coronary Artery Vsmc, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+smooth+muscle+cells+human+coronary+artery+vsmc/vascular+smooth+muscle+cells+human+coronary+artery+vsmc/pm16915039-78-6-13
Average 90 stars, based on 1 article reviews
Vascular Smooth Muscle Cells Human Coronary Artery Vsmc, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+smooth+muscle+cells+human+coronary+artery+vsmc/vascular+smooth+muscle+cells+human+coronary+artery+vsmc/pm16915039-78-6-13
Average 90 stars, based on 1 article reviews
vascular smooth muscle cells human coronary artery vsmc - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Migration:Article Title: A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. Article Snippet: Background Calcium antagonists have been shown to reduce atherogenesis and improve clinical outcomes in atherosclerotic vascular disease.. No study has so far, however, addressed the effects of calcium antagonists on stent-associated neointimal formation.. We therefore investigated whether a third-generation calcium antagonist, azelnidipine, attenuates in-stent neointimal formation in non-human primates. Cell Culture:Article Title: A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. Article Snippet: Background Calcium antagonists have been shown to reduce atherogenesis and improve clinical outcomes in atherosclerotic vascular disease.. No study has so far, however, addressed the effects of calcium antagonists on stent-associated neointimal formation.. We therefore investigated whether a third-generation calcium antagonist, azelnidipine, attenuates in-stent neointimal formation in non-human primates. |